Table 1.
Baseline characteristics in 50 as-treated patients
| Patients (n = 50) | |
|---|---|
| Age, years | 64 (41–74) |
| <65years | 24 (48) |
| ≥65 years | 26 (52) |
| Sex | |
| Male | 39 (78) |
| Female | 11 (22) |
| ECOG performance status | |
| 0 | 12 (24) |
| 1 | 38 (76) |
| Disease stage | |
| IVA | 3 (6) |
| IVB | 47 (94) |
| Number of metastatic sites | |
| 1 | 11 (22) |
| 2 | 32 (64) |
| ≥2 | 7 (14) |
| Metastatic sites | |
| Lymph node | 48 (96) |
| Lung | 25 (50) |
| Liver | 7 (14) |
| Prior surgery | 17 (34) |
| Prior radiotherapy | 8 (16) |
| Baseline PD-L1 CPS a | |
| <1 | 26 (52) |
| ≥1 | 12 (24) |
| <10 | 34 (68) |
| ≥10 | 4 (8) |
| Unknown | 12 (24) |
Data were expressed as median (range) or no (%)
ECOG Eastern Cooperative Oncology Group, PD-L1 programmed death ligand-1, CPS combined positive score
a PD-L1 positivity was not required and PD-L1 status was assessed in 38 patients